| Filed On | Filing |
|---|---|
| 06 Nov 2026 |
8-K: Results of Operations and Financial Condition
CyPath® Lung test unit sales double year to date over 2025, with solid gains in physician utilization and recurring orders; testing revenue increases 79% year-to-date |
| 29 Oct 2026 |
8-K: Other Events
bioAffinity Technologies Highlights Importance of Link Between Early Lung Cancer Detection and Curative Treatment During National Lung Cancer Awareness Month |
| 15 Oct 2026 |
8-K: Other Events
Presentation to address current challenges in pulmonary nodule management and to discuss preliminary research data from the ongoing development of a new, investigational test for asthma and COPD |
| 13 Oct 2026 |
8-K: Other Events
bioAffinity Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and Drug-Related Receptors at CHEST 2026 |
| 09 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
Subject to the terms and conditions herein (this “Agreement”), bioAffinity Technologies Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of approximately $4,000,000 of registered and unregistered sec... |
| 08 Oct 2026 |
8-K: Other Events
bioAffinity Technologies Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath® Lung and AI-Built Algorithm |
| 06 Oct 2026 |
8-K: Other Events
SAN ANTONIO, TEXAS — October 6, 2026 — bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced that... |
| 30 Sep 2026 |
8-K: Other Events
bioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath® Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICAL |
| 22 Sep 2026 |
8-K: Other Events
bioAffinity Technologies to Present Positive Clinical and Veteran-Focused Data on CyPath® Lung at NAVREF 2026 Annual Conference |
| 17 Sep 2026 |
8-K: Other Events
bioAffinity Technologies Announces Grant of Hong Kong Patent for Company’s CyPath® Lung Noninvasive Lung Cancer Diagnostic |
| 11 Sep 2026 |
8-K: Regulation FD Disclosure
bioAffinity Technologies, Inc., a Delaware corporation, (the “Company”) has prepared presentation materials (the “Presentation Materials”) that management intends to use from time to time in presentations about the Company’s operations a... |
| 09 Sep 2026 |
8-K: Other Events
SAN ANTONIO, TX — September 9, 2026 — bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced that ... |
| 03 Sep 2026 |
8-K: Other Events
SAN ANTONIO, Texas – September 3, 2026 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics for the early detection of lung cancer and other lung diseases, today announced tha... |
| 01 Sep 2026 |
8-K: Other Events
More than 680,000 Americans living with a history of lung cancer represent a significant population requiring ongoing surveillance |
| 20 Aug 2026 |
8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
SAN ANTONIO, TX – August 20, 2026 – bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it will effect a 1-... |
| 18 Aug 2026 |
8-K: Other Events
New partner’s national sales force will market CyPath Lung to federal healthcare agencies, including VA medical centers nationwide |
| 14 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into effective as of August 12, 2026, between BIOAFFINITY TECHNOLOGIES, INC., a Delaware corporation (the “Company”), and each purchaser identified on the signatur... |
| 07 Aug 2026 |
8-K: Results of Operations and Financial Condition
Pipeline expands to include development of precision diagnostics for asthma and COPD and dermally delivered skin cancer therapeutics |
| 31 Jul 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On July 30, 2026, bioAffinity Technologies, Inc., a Delaware corporation (the “Company”) received written notice (the “Staff Determination”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying t... |
| 27 Jul 2026 |
8-K: Other Events
bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung |
Loading...